Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVA6000 in Locally Advanced or Metastatic Solid Tumours
NCT04969835Phase 1Active, not recruiting
- Sponsor
- Avacta
- Start
- Jul 2021
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label trial of AVA6000 in salivary gland tumor, urothelial carcinoma (UC), ovarian carcinoma and 2 more, sponsored by Avacta. Primary endpoints: Dose-limiting toxicities up to 28 days, Adverse events and 2 more. Started Jul 2021; status: active, not recruiting.
02
Drugs
AVA6000
03
Conditions
salivary gland tumorurothelial carcinoma (UC)ovarian carcinomabreast cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04969835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969835.